无创检测策略分层管理进展性慢性肝病应用研究进展

doi:10.3969/j.issn.1672-5069.2026.01.002

摘要/Abstract

Key words: Chronic liver diseases, Non-invasive testing, Hierarchical management, Prognosis

程欢, 王海玉, 沈国俊, 陈金军. 无创检测策略分层管理进展性慢性肝病应用研究进展[J]. 实用肝脏病杂志, 2026, 29(1): 5-8.

Cheng Huan, Wang Haiyu, Shen Guojun, et al. Non-invasive testing strategies in the stratified management of patients with advanced chronic liver disease[J]. Journal of Practical Hepatology, 2026, 29(1): 5-8.

参考文献

[1] Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015, 63(3): 743-752.
[2] Papatheodoridi M, Hiriart J B, Lupsor-Platon M, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol, 2021, 74(5): 1109-1116.
[3] Ji Y, Li J, He Q, et al. Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD. J Hepatol, 2021, 75(5): 1243-1245.
[4] Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol, 2022, 76(4): 959-974.
[5] Berzigotti A, Tsochatzis E, Boursier J, et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol, 2021, 75(3): 659-689.
[6] Wang K, Lu X, Zhou H, et al. Deep learning radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study. Gut, 2019, 68(4): 729-741.
[7] Guglielmo F F, Barr R G, Yokoo T, et al. Liver fibrosis, fat, and iron evaluation with MRI and fibrosis and fat evaluation with US: a practical guide for radiologists. Radiographics, 2023, 43(6): e220181.
[8] Jachs M, Hartl L, Simbrunner B, et al. The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension. Clin Gastroenterol Hepatol, 2023, 21(7): 1854-1863,e10.
[9] Sterling R K, Asrani S K, Levine D, et al. AASLD practice guideline on noninvasive liver disease assessment of portal hypertension. Hepatology, 2025, 81(3): 1060-1085.
[10] Sanyal A J, Harrison S A, Ratziu V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology, 2019, 70(6): 1913-1927.
[11] Loomba R, Adams L A. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology, 2019, 70(6): 1885-1888.
[12] Mattos A A, Mattos A Z, Sartori G D P, et al. The role of elastography in clinically significant portal hypertension. Arq Gastroenterol, 2023, 60(4): 525-535.
[13] Stafylidou M, Paschos P, Katsoula A, et al. Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2019, 17(9): 1744-1755,e11.
[14] Wu CW, Lui RN, Wong VW, et al. Baveno VII criteria is an accurate risk stratification tool to predict high-risk varices requiring intervention and hepatic events in patients with advanced hepatocellular carcinoma. Cancers (Basel), 2023, 15(9): 2480.
[15] Vanderschueren E, Armandi A, Kwanten W, et al. Spleen stiffness-based algorithms are superior to Baveno VI criteria to rule out varices needing treatment in patients with advanced chronic liver disease. Am J Gastroenterol, 2024, 119(8): 1515-1524.
[16] Zhang X, Song J, Zhang Y, et al. Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis. J Hepatol, 2023, 78(3): 574-583.
[17] Dajti E, Villanueva C, Berzigotti A, et al. Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial. J Hepatol, 2025, 82(3): 490-498.
[18] Ma J, Gong X, Luo J, et al. Impact of intrahepatic venovenous shunt on hepatic venous pressure gradient measurement. J Vasc Interv Radiol, 2020, 31(12): 2081-2088.
[19] Dajti E, Ravaioli F, Zykus R, et al. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis. Lancet Gastroenterol Hepatol, 2023, 8(9): 816-828.
[20] Jachs M, Sandmann L, Hartl L, et al. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta. J Hepatol, 2024, 81(2): 248-257.
[21] Mandorfer M, Aigner E, Cejna M, et al. Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV). Wien Klin Wochenschr, 2023, 135(Suppl 3): 493-523.
[22] Celsa C, Veneziano M, Di Giorgio F M, et al. Non-invasive diagnostic tests for portal hypertension in patients with HBV- and HCV-related cirrhosis: a comprehensive review. Medicina (Kaunas), 2024, 60(5): 690.
[23] Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2019, 393(10181): 1597-1608.
[24] Rasmussen D N, Thiele M, Johansen S, et al. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J Hepatol, 2021, 75(5): 1017-1025.
[25] Thorhauge K H, Semmler G, Johansen S, et al. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease. J Hepatol, 2024, 81(1): 23-32.
[26] Gawrieh S, Vilar-Gomez E, Wilson L A, et al. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD. J Hepatol, 2024, 81(4): 600-608.
[27] Wang H, Liang W, Zhou L, et al. Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis. Clin Mol Hepatol, 2025[ahead of print].
[28] Semmler G, Alonso López S, Pons M, et al. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure. J Hepatol, 2024, 81(1): 76-83.
[29] Lens S, Baiges A, Alvarado-Tapias E, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol, 2020, 73(6): 1415-1424.
[30] Semmler G, Lens S, Meyer E L, et al. Non-invasive tests for clinically significant portal hypertension after HCV cure. J Hepatol, 2022, 77(6): 1573-1585.
[31] Shearer J E, Jones R, Parker R, et al. The natural history of advanced chronic liver disease defined by transient elastography. Clin Gastroenterol Hepatol, 2023, 21(3): 694-703,e8.
[32] Gidener T, Ahmed O T, Larson J J, et al. Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD. Clin Gastroenterol Hepatol, 2021, 19(9): 1915-1924,e6.
[33] Higuchi M, Tamaki N, Kurosaki M, et al. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther, 2022, 55(3): 292-301.
[34] Semmler G, Hartl L, Mendoza Y P, et al. Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension. Hepatology, 2024, 80(4): 887-900.
[35] Jachs M, Hartl L, Simbrunner B, et al. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient. J Hepatol, 2024, 80(5): 744-752.